JP4594534B2 - 分解再構築ウイルス様粒子を含むヒトパピローマウイルスワクチン - Google Patents
分解再構築ウイルス様粒子を含むヒトパピローマウイルスワクチン Download PDFInfo
- Publication number
- JP4594534B2 JP4594534B2 JP2000607656A JP2000607656A JP4594534B2 JP 4594534 B2 JP4594534 B2 JP 4594534B2 JP 2000607656 A JP2000607656 A JP 2000607656A JP 2000607656 A JP2000607656 A JP 2000607656A JP 4594534 B2 JP4594534 B2 JP 4594534B2
- Authority
- JP
- Japan
- Prior art keywords
- vlp
- buffer
- nacl
- hpv
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002245 particle Substances 0.000 title claims description 25
- 229940124866 human papillomavirus vaccine Drugs 0.000 title claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 117
- 241000701806 Human papillomavirus Species 0.000 claims description 114
- 150000003839 salts Chemical class 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 61
- 239000011780 sodium chloride Substances 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 48
- 229910052782 aluminium Inorganic materials 0.000 claims description 40
- 239000000872 buffer Substances 0.000 claims description 38
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 35
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 35
- 229920000053 polysorbate 80 Polymers 0.000 claims description 35
- 229940068968 polysorbate 80 Drugs 0.000 claims description 35
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 34
- 238000010494 dissociation reaction Methods 0.000 claims description 30
- 230000005593 dissociations Effects 0.000 claims description 30
- 238000003860 storage Methods 0.000 claims description 26
- 239000002671 adjuvant Substances 0.000 claims description 24
- 238000000502 dialysis Methods 0.000 claims description 21
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 17
- 229910019142 PO4 Inorganic materials 0.000 claims description 15
- 239000007983 Tris buffer Substances 0.000 claims description 15
- 239000010452 phosphate Substances 0.000 claims description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 13
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 12
- 238000011026 diafiltration Methods 0.000 claims description 11
- 238000000108 ultra-filtration Methods 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 9
- 239000008363 phosphate buffer Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 description 59
- 230000015556 catabolic process Effects 0.000 description 58
- 238000004458 analytical method Methods 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 239000000243 solution Substances 0.000 description 32
- 239000003638 chemical reducing agent Substances 0.000 description 23
- 238000000338 in vitro Methods 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- 239000002736 nonionic surfactant Substances 0.000 description 17
- 229960005486 vaccine Drugs 0.000 description 16
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 15
- 238000009826 distribution Methods 0.000 description 14
- 238000005199 ultracentrifugation Methods 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000002738 chelating agent Substances 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 229920000447 polyanionic polymer Polymers 0.000 description 6
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 4
- 241000701828 Human papillomavirus type 11 Species 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012537 formulation buffer Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960002566 papillomavirus vaccine Drugs 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- ZZIFPJZQHRJERU-WDSKDSINSA-N Glu-Cys-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O ZZIFPJZQHRJERU-WDSKDSINSA-N 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000006076 specific stabilizer Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12652899P | 1999-03-26 | 1999-03-26 | |
| US60/126,528 | 1999-03-26 | ||
| US09/524,624 | 2000-03-13 | ||
| US09/524,624 US6245568B1 (en) | 1999-03-26 | 2000-03-13 | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
| PCT/US2000/007595 WO2000057906A1 (fr) | 1999-03-26 | 2000-03-22 | Vaccin contre le papillomavirus aux particules viro-induites desassemblees et reassemblees |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002540167A JP2002540167A (ja) | 2002-11-26 |
| JP4594534B2 true JP4594534B2 (ja) | 2010-12-08 |
Family
ID=26824774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000607656A Expired - Lifetime JP4594534B2 (ja) | 1999-03-26 | 2000-03-22 | 分解再構築ウイルス様粒子を含むヒトパピローマウイルスワクチン |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6245568B1 (fr) |
| EP (1) | EP1165126B1 (fr) |
| JP (1) | JP4594534B2 (fr) |
| KR (1) | KR20020013516A (fr) |
| AR (1) | AR023166A1 (fr) |
| AT (1) | ATE339222T1 (fr) |
| AU (1) | AU778937B2 (fr) |
| CA (1) | CA2368391C (fr) |
| CY (4) | CY1105779T1 (fr) |
| DE (4) | DE122007000034I1 (fr) |
| DK (1) | DK1165126T3 (fr) |
| ES (1) | ES2270822T3 (fr) |
| FR (1) | FR07C0026I2 (fr) |
| LT (1) | LTC1165126I2 (fr) |
| LU (3) | LU91326I2 (fr) |
| NL (3) | NL300270I1 (fr) |
| PT (1) | PT1165126E (fr) |
| SI (1) | SI1165126T1 (fr) |
| WO (1) | WO2000057906A1 (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6962777B1 (en) * | 1997-09-05 | 2005-11-08 | Medimmune, Inc. | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents |
| US7351533B2 (en) | 1997-09-05 | 2008-04-01 | Medimmune, Inc. | In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents |
| ATE426803T1 (de) * | 1999-12-09 | 2009-04-15 | Medimmune Inc | In-vitro-methode zur zerlegung und zum wiederzusammenfugen von papillomavirusartigen partikeln |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| CN100350972C (zh) * | 2001-07-26 | 2007-11-28 | 启龙股份公司 | 含有铝佐剂和组氨酸的疫苗 |
| DE10137102A1 (de) * | 2001-07-30 | 2003-02-27 | Deutsches Krebsforsch | Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung |
| US20060073530A1 (en) * | 2001-08-15 | 2006-04-06 | Olaf Schneewind | Methods and compositions involving sortase B |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US20040121465A1 (en) * | 2002-02-14 | 2004-06-24 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| DE10237639A1 (de) * | 2002-08-13 | 2004-02-26 | Martin-Luther-Universität Halle-Wittenberg | Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle |
| GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| BR0315767A (pt) | 2002-11-01 | 2005-09-06 | Glaxosmithkline Biolog Sa | Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador |
| EA200701633A1 (ru) | 2002-12-20 | 2007-12-28 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1 |
| US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| EP1785433A4 (fr) * | 2004-07-01 | 2008-10-01 | Tokyo Inst Tech | Construction ressemblant a une particule virale et procede servant a former celle-ci dans des conditions physiologiques |
| RU2442822C2 (ru) * | 2005-01-25 | 2012-02-20 | Вайет Рисерч Айрлэнд Лимитед | Вещества, защищающие клетки от рассечения при сборе микрофильтрацией |
| US7759104B2 (en) * | 2005-07-14 | 2010-07-20 | Mayo Foundation For Medical Education And Research | Paramyxoviridae virus preparations |
| WO2007020871A1 (fr) * | 2005-08-12 | 2007-02-22 | Astellas Pharma Inc. | Technique de stabilisation de preparation de yw753 |
| BRPI0520505B1 (pt) * | 2005-09-01 | 2015-03-31 | José Luis Nuño Ayalá | Fórmula estabilizadora de vacinas com antígenos vivos para uso em sistemas de vacinação em massa |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| JP2009536958A (ja) * | 2006-05-11 | 2009-10-22 | ベクトン・ディキンソン・アンド・カンパニー | 細胞からのタンパク質抽出方法 |
| US9207240B2 (en) | 2007-11-14 | 2015-12-08 | Arbor Vita Corporation | Method of efficient extraction of protein from cells |
| US8420128B2 (en) * | 2008-03-31 | 2013-04-16 | Morinaga Milk Industry Co., Ltd. | Method of imparting heat resistance to lactoferrin |
| JP5916610B2 (ja) | 2009-09-03 | 2016-05-11 | ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ | 直接的な化学的溶解のための方法および組成物 |
| AU2011294776B2 (en) | 2010-08-23 | 2016-02-04 | Wyeth Llc | Stable formulations of Neisseria meningitidis rLP2086 antigens |
| CA2809758C (fr) | 2010-09-10 | 2021-07-13 | Wyeth Llc | Variants non-lipidiques des antigenes orf 2086 de neisseria meningitidis |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| EP4043029A1 (fr) | 2012-03-09 | 2022-08-17 | Pfizer Inc. | Compositions de neisseria meningitidis et procédés associés |
| WO2013139744A1 (fr) | 2012-03-18 | 2013-09-26 | Glaxosmithkline Biologicals S.A. | Procédé de vaccination contre le papillomavirus humain |
| KR101559622B1 (ko) * | 2012-07-30 | 2015-10-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
| ES2685894T3 (es) | 2013-03-08 | 2018-10-15 | Pfizer Inc. | Polipéptidos de fusión inmunogénicos |
| MX369534B (es) | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
| RU2723045C2 (ru) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их получения |
| MX2019009011A (es) | 2017-01-31 | 2019-09-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos. |
| WO2018152505A1 (fr) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Production acellulaire efficace de vecteurs de transfert du gène du virus à papillomes |
| CN110987571A (zh) * | 2019-12-31 | 2020-04-10 | 广州金域医学检验中心有限公司 | 一种单克隆多聚体m蛋白解聚方法 |
| CN111812313B (zh) * | 2020-06-22 | 2021-10-08 | 北京生物制品研究所有限责任公司 | 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2278684C (fr) * | 1997-02-06 | 2007-04-10 | Merck & Co., Inc. | Conservateurs sans thimerosal pour vaccins |
| EE9900612A (et) | 1997-04-08 | 2000-08-15 | Merck & Co., Inc. | Inimese papilloomiviiruse stabiliseeritud preparaadid |
| EP1000157A1 (fr) | 1997-07-03 | 2000-05-17 | University Technology Corporation | Compositions renfermant des capsomeres de papillomavirus humain homogene, leurs procedes de production et leurs procedes d'utilisation en tant qu'agents diagnostiques, prophylactiques ou therapeutiques |
-
2000
- 2000-03-13 US US09/524,624 patent/US6245568B1/en not_active Expired - Lifetime
- 2000-03-22 DE DE200712000034 patent/DE122007000034I1/de active Pending
- 2000-03-22 EP EP00918248A patent/EP1165126B1/fr not_active Expired - Lifetime
- 2000-03-22 DE DE200712000033 patent/DE122007000033I1/de active Pending
- 2000-03-22 DE DE200712000032 patent/DE122007000032I1/de active Pending
- 2000-03-22 PT PT00918248T patent/PT1165126E/pt unknown
- 2000-03-22 SI SI200030893T patent/SI1165126T1/sl unknown
- 2000-03-22 AU AU39093/00A patent/AU778937B2/en not_active Expired
- 2000-03-22 ES ES00918248T patent/ES2270822T3/es not_active Expired - Lifetime
- 2000-03-22 WO PCT/US2000/007595 patent/WO2000057906A1/fr active IP Right Grant
- 2000-03-22 KR KR1020017012229A patent/KR20020013516A/ko not_active Application Discontinuation
- 2000-03-22 DK DK00918248T patent/DK1165126T3/da active
- 2000-03-22 DE DE60030698T patent/DE60030698T2/de not_active Expired - Lifetime
- 2000-03-22 AT AT00918248T patent/ATE339222T1/de active
- 2000-03-22 JP JP2000607656A patent/JP4594534B2/ja not_active Expired - Lifetime
- 2000-03-22 CA CA2368391A patent/CA2368391C/fr not_active Expired - Lifetime
- 2000-03-24 AR ARP000101345A patent/AR023166A1/es unknown
-
2001
- 2001-01-30 US US09/772,365 patent/US20010021385A1/en not_active Abandoned
-
2006
- 2006-11-14 CY CY20061101649T patent/CY1105779T1/el unknown
-
2007
- 2007-03-13 LU LU91326C patent/LU91326I2/fr unknown
- 2007-03-13 LU LU91328C patent/LU91328I2/fr unknown
- 2007-03-13 NL NL300270C patent/NL300270I1/nl unknown
- 2007-03-13 NL NL300268C patent/NL300268I1/nl unknown
- 2007-03-13 LU LU91327C patent/LU91327I2/fr unknown
- 2007-03-13 NL NL300269C patent/NL300269I2/nl unknown
- 2007-03-16 CY CY2007009C patent/CY2007009I2/el unknown
- 2007-03-16 CY CY200700010C patent/CY2007010I2/el unknown
- 2007-03-16 CY CY200700008C patent/CY2007008I1/el unknown
- 2007-03-19 LT LTPA2007002C patent/LTC1165126I2/lt unknown
- 2007-03-20 FR FR07C0026C patent/FR07C0026I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4594534B2 (ja) | 分解再構築ウイルス様粒子を含むヒトパピローマウイルスワクチン | |
| JP4841726B2 (ja) | ヒトパピローマウイルスワクチン製剤 | |
| JP4546092B2 (ja) | ワクチン | |
| CA2834618C (fr) | Formulation de vaccin contre le papillomavirus comprenant un adjuvant a l'aluminium, et procede de production correspondant | |
| JP5388842B2 (ja) | インフルエンザワクチン含有凍結乾燥製剤、及びその製造方法 | |
| TW200400046A (en) | Viral antigens | |
| US20240075124A1 (en) | Stable formulation of human papillomavirus virus-like particle vaccine | |
| JP4689914B2 (ja) | 改善された特性を有するヒトパピローマウイルスウイルス様粒子の新規製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100419 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100726 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100824 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100917 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130924 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4594534 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130924 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130924 Year of fee payment: 3 |
|
| S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130924 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130924 Year of fee payment: 3 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130924 Year of fee payment: 3 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130924 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |